The degree to which tumor-expressed PD-L2 can substitute for PD-L1 as an immunosuppressing agent is not well-established, but an association between resistance to anti-PD-L1 immunotherapies and PD-L2 overexpression suggests an important role for PD-L2 in immune escape (108). This evidence concerns the gene CD274 and neoplasm.